A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
Authors' conclusion
Enavogliflozin added to metformin was tolerated well for up to 52 weeks and provided continual glycaemic control in type 2 diabetes mellitus, along with a significant increase in the urine glucose-creatinine ratio.
Study context
- Population
- Patients with T2D on metforminextension: 82 maintenance, 77 switch
- Participants
- 82 vs 77
- Comparison
- Enavogliflozin maintained vs switched from dapagliflozin to enavogliflozin, added to metformin
- Maintenancen = 82
- Switchn = 77
- Primary endpoint
- Long-term safety and efficacy of enavogliflozin 0.3 mg/day added to metformin
- Follow-up
- Up to 52 weeks
Methodological details24-week randomised double-blind period, 28-week open-label extension
- 24-week randomised double-blind period
- 28-week open-label extension
Primary result
As reported in the abstract
Adverse drug reactions
Further findings
HbA1c reduction from baseline · week 52
P vs baseline Maintenance p < .0001 · Switch p < .0001
HbA1c <7% achieved · week 52
FPG reduction from baseline · week 52
P vs baseline Maintenance p < .0001 · Switch p < .0001
Increase in urine glucose-creatinine ratio · week 52
- Increase in urine glucose-creatinine ratio — Significant increase vs baseline
- p < .0001
Original publication
A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study. Diabetes Obes Metab. Published 8 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →